Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.47 |
| ▸ | ITGAV | P06756 | 3/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13762119 | 0.91 | L3MBTL1 (0.58) | HDAC1HDAC6ITGB1ITGA4L3MBTL1 | |
| SCHEMBL13927753 | 0.87 | L3MBTL1 (0.61) | ITGB1ITGA4L3MBTL1ATM | |
| SCHEMBL4524464 | 0.85 | ITGB1 (0.52) | HDAC1HDAC6ITGB1ITGA4L3MBTL1 | |
| SCHEMBL8230999 | 0.85 | ITGB1 (0.52) | HDAC1HDAC6ITGB1ITGA4L3MBTL1 | |
| SCHEMBL4194979 | 0.84 | NLRP3 (0.59) | ITGB1ITGA4L3MBTL1ATMITGB3 | |
| SCHEMBL8232058 | 0.84 | NLRP3 (0.59) | ITGB1ITGA4L3MBTL1ATMITGB3 | |
| SCHEMBL13755101 | 0.82 | ITGB1 (0.51) | HDAC1HDAC6ITGB1ITGA4L3MBTL1 | |
| SCHEMBL5788218 | 0.80 | HDAC1 (0.55) | HDAC1HDAC6ITGB1ITGA4ITGA5 | |
| SCHEMBL21519805 | 0.79 | ITGA4 (0.54) | HDAC1HDAC6ITGB1ITGA4ATM | |
| SCHEMBL21519762 | 0.79 | HDAC1 (0.54) | HDAC1HDAC6ITGB1ITGA4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGA1, ITGB1, ITGA5 | HDAC1 978/4885HDAC6 767/4885ITGB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.